Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410147 | 0.94 | ALDH1A1 (0.56) | ALDH1A1TP53TSHRACE2MAPT | |
| SCHEMBL1410472 | 0.91 | ALDH1A1 (0.62) | ALDH1A1TP53TSHRACE2MAPT | |
| SCHEMBL1410541 | 0.86 | TSHR (0.52) | ALDH1A1TP53TSHRACE2MAPT | |
| SCHEMBL16667714 | 0.86 | TSHR (0.48) | ALDH1A1TP53TSHRACE2MAPT | |
| SCHEMBL23924942 | 0.83 | ALDH1A1 (0.72) | ALDH1A1TP53TSHRACE2MAPK1 | |
| SCHEMBL28194820 | 0.83 | ALDH1A1 (0.72) | ALDH1A1TP53TSHRACE2MAPK1 | |
| SCHEMBL30109011 | 0.83 | ALDH1A1 (0.72) | ALDH1A1TP53TSHRACE2MAPK1 | |
| SCHEMBL1410266 | 0.83 | ALDH1A1 (0.56) | ALDH1A1TP53TSHRACE2MAPT | |
| SCHEMBL495398 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRACE2MAPT | |
| SCHEMBL495579 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRACE2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148969-B1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | KETOGEN INC (CA) | 2020-11-11 | — | — | EP | disclosed |
| EP-3148969-B1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | KETOGEN INC (CA) | 2020-11-11 | — | — | EP | disclosed |
| EP-3148969-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen Inc. (CA) | 2017-04-05 | — | — | EP | disclosed |
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen, Inc. (CA) | 2017-02-16 | — | — | US | disclosed |
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen, Inc. (CA) | 2017-02-16 | — | — | US | disclosed |
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen, Inc. (CA) | 2017-02-16 | — | — | US | disclosed |
| US-9481637-B2 | Compounds for the treatment of seizures and other central nervous systems disorders and conditions | Ketogen Inc. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9481637-B2 | Compounds for the treatment of seizures and other central nervous systems disorders and conditions | Ketogen Inc. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9481637-B2 | Compounds for the treatment of seizures and other central nervous systems disorders and conditions | Ketogen Inc. (CA) | 2016-11-01 | — | — | US | disclosed |
| WO-2015184542-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen Inc. (CA) | 2015-12-10 | — | — | WO | disclosed |
| EP-2437718-B1 | PHENOL ESTER AS PERFUMING INGREDIENT | FIRMENICH & CIE (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-20120165517-A1 | CELLULOSE DERIVATIVE, THERMO-MOLDING MATERIAL, MOLDED BODY AND METHOD FOR PREPARATION THEREOF, AND CASE FOR ELECTRIC AND ELECTRONIC DEVICES | FUJIFILM CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2465899-A1 | CELLULOSE DERIVATIVE, THERMOFORMED MATERIAL, MOLDED BODY, PRODUCTION METHOD THEREFOR, AND CASING FOR ELECTRICAL AND ELECTRONIC EQUIPMENT | FUJIFILM Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120146468-A1 | CELLULOSE DERIVATIVE, RESIN COMPOSITION, MOLDED BODY, METHOD FOR PREPARATION THEREOF, AND CASE FOR ELECTRIC AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| CN-102458349-A | Phenol esters as perfuming ingredients | FIRMENICH & CIE | 2012-05-16 | — | — | CN | disclosed |
| EP-2437718-A1 | PHENOL ESTER AS PERFUMING INGREDIENT | Firmenich S.A. (CH) | 2012-04-11 | — | — | EP | disclosed |
| US-20120045408-A1 | PHENOL ESTER AS PERFUMING INGREDIENT | FIRMENICH SA (CH) | 2012-02-23 | — | — | US | disclosed |
| US-20110098463-A1 | CELLULOSE DERIVATIVE AND METHOD FOR PRODUCING THE SAME, CELLULOSE RESIN COMPOSITION, MOLDED MATTER AND METHOD FOR MAKING THE SAME, AND ELECTRICAL AND ELECTRONIC EQUIPMENT HOUSING | FUJIFILM CORPORATION (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2295470-A1 | CELLULOSE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF, CELLULOSE RESIN COMPOSITION, MOLDED ARTICLE AND METHOD FOR PRODUCTION THEREOF, AND HOUSING FOR ELECTROCHEMICAL DEVICE | FUJIFILM Corporation (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010140076-A1 | PHENOL ESTER AS PERFUMING INGREDIENT | FIRMENICH SA (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045408-A1 | PHENOL ESTER AS PERFUMING INGREDIENT | HPD, CYP2E1, CYP2B6 | ALDH1A1 1292/4885TP53 2414/4885TSHR 4085/4885 |
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | ALDH1A1 640/4885TP53 4855/4885TSHR 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.